Therapy News and Research

RSS

Intra-arterial therapy no more effective than IV t-PA in treating acute ischemic stroke

A stroke survivor's chances of living independently after 90 days are not improved by the use of devices inserted into the artery to dissolve or remove a stroke-causing clot shortly after the onset of symptoms, according to a randomized controlled trial involving 656 patients.

11 Feb 2013

sFRP3 protein appears to be target of both antidepressant drugs and electroconvulsive therapy

Through a series of investigations in mice and humans, Johns Hopkins researchers have identified a protein that appears to be the target of both antidepressant drugs and electroconvulsive therapy.

11 Feb 2013

Diet high in fruits and vegetables may help protect kidneys of patients with CKD

Adding fruits and vegetables to the diet may help protect the kidneys of patients with chronic kidney disease (CKD) with too much acid build-up, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).

10 Feb 2013

Fbxl10 molecule plays a crucial role in differentiation of embryonic stem cells

A single embryonic stem cell can develop into more than 200 specialized cell types that make up our body. This maturation process is called differentiation and is tightly regulated. If the regulation is lost, specialized cells cannot develop correctly during development. In adulthood, the specialized cells may forget their identity and develop into cancer cells.

10 Feb 2013

SUVmax may help indicate progression-free survival in stage I NSCLC patients treated with SBRT

SUVmax (Maximum Standardized Uptake Value) may be a significant and clinically independent marker to indicate progression-free survival in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT), according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium.

10 Feb 2013

Infusions of regulatory T cells turn off autoimmune attack on joints

Farber Cancer Institute scientists have demonstrated a new strategy for treating autoimmune disease that successfully blocked the development of rheumatoid arthritis in a mouse model. They say it holds promise for improved treatment of arthritis and other autoimmune disorders in people.

10 Feb 2013

Northwestern Medicine expert offers tips to battle seasonal affective disorder

Winter is in full force. With short days and less exposure to sunlight, everyone feels less energetic and more people are vulnerable to depression. Seasonal Affective Disorder (SAD), or winter depression, is a mood disorder related to seasonal variations of light. Symptoms start in late fall and oftentimes last until April or early spring. It affects between 10 to 20 percent of Americans, primarily younger adults and women.

10 Feb 2013

Combination of two antibodies prevents growth and spread of triple-negative breast tumors

Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are particularly aggressive and notoriously difficult to treat.

10 Feb 2013

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.

10 Feb 2013

Single gene therapy session can cure diabetes

Researchers from the Universitat Aut-noma de Barcelona (UAB), led by F-tima Bosch, have shown for the first time that it is possible to cure diabetes in large animals with a single session of gene therapy. As published this week in Diabetes, the principal journal for research on the disease, after a single gene therapy session, the dogs recover their health and no longer show symptoms of the disease.

10 Feb 2013

Top prostate cancer surgeon to conduct free men's health screening

On Saturday, February 16, 2013, top prostate cancer surgeon, Dr. David Samadi , will conduct free prostate cancer screenings at the Chian Federation, 4401 Broadway in Astoria, New York 11103.

10 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from the combined results of two Phase 3 studies of PA32540, an antiplatelet therapy of enteric-coated (EC) and immediate-release omeprazole, in patients with previous cerebrovascular disease.

10 Feb 2013

MMRF joins multiple myeloma community in celebrating FDA accelerated approval of Pomalyst

The Multiple Myeloma Research Foundation (MMRF) today joined the multiple myeloma community in celebrating the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval of Pomalyst (Celgene Corporation, pomalidomide) for the treatment of patients with relapsed and refractory multiple myeloma who no longer respond to currently available treatments.

10 Feb 2013

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US.

10 Feb 2013

LPA genetic variant increases risk of heart valve calcification

Researchers have found a genetic variant that doubles the likelihood that people will have calcium deposits on their aortic valve. Such calcification, if it becomes severe, can cause narrowing or a blockage of the aortic valve, a condition called aortic stenosis.

9 Feb 2013

TIC10 may improve usefulness of TRAIL protein in cancer therapy

A compound that stimulates the production of a tumor-fighting protein may improve the usefulness of the protein in cancer therapy, according to a team of researchers.

9 Feb 2013

Etanercept no better than prednisone for COPD exacerbations

Results from a randomized, double-blind, controlled trial suggest that the tumor necrosis factor α antagonist etanercept is no more effective than standard therapy with prednisone for the treatment of acute exacerbations in patients with chronic obstructive pulmonary disease.

8 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Therapy News and Research

Intra-arterial therapy no more effective than IV t-PA in treating acute ischemic stroke

sFRP3 protein appears to be target of both antidepressant drugs and electroconvulsive therapy

Diet high in fruits and vegetables may help protect kidneys of patients with CKD

Fbxl10 molecule plays a crucial role in differentiation of embryonic stem cells

SUVmax may help indicate progression-free survival in stage I NSCLC patients treated with SBRT

Infusions of regulatory T cells turn off autoimmune attack on joints

Northwestern Medicine expert offers tips to battle seasonal affective disorder

Combination of two antibodies prevents growth and spread of triple-negative breast tumors

Positive results from NCI-sponsored bevacizumab trial on cervical cancer

Single gene therapy session can cure diabetes

Top prostate cancer surgeon to conduct free men's health screening

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Positive data from POZEN's PA32540 Phase 3 studies presented at AHA 2013 stroke conference

MMRF joins multiple myeloma community in celebrating FDA accelerated approval of Pomalyst

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

LPA genetic variant increases risk of heart valve calcification

TIC10 may improve usefulness of TRAIL protein in cancer therapy

Etanercept no better than prednisone for COPD exacerbations

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News